Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 245

1.

Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing.

Mansfield AS, Park BH, Mullane MP.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):873-880. doi: 10.1200/EDBK_208339. Review.

PMID:
30231389
2.

Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.

Pegram MD, Zong Y, Yam C, Goetz MP, Moulder SL.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):65-77. doi: 10.1200/EDBK_200715. Review.

PMID:
30231328
3.

Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era.

Lyon TD, Gershman B, Shah PH, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC.

Urol Oncol. 2018 Nov;36(11):499.e1-499.e7. doi: 10.1016/j.urolonc.2018.08.008. Epub 2018 Sep 15.

PMID:
30228096
4.

Clinical update on K-Ras targeted therapy in gastrointestinal cancers.

Pant S, Hubbard J, Martinelli E, Bekaii-Saab T.

Crit Rev Oncol Hematol. 2018 Oct;130:78-91. doi: 10.1016/j.critrevonc.2018.07.011. Epub 2018 Aug 2. Review.

PMID:
30196915
5.

Novel targeted treatment options for advanced cholangiocarcinoma.

Mahipal A, Kommalapati A, Tella SH, Lim A, Kim R.

Expert Opin Investig Drugs. 2018 Sep;27(9):709-720. doi: 10.1080/13543784.2018.1512581. Epub 2018 Aug 30. Review.

PMID:
30124336
6.

Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.

Orozco CA, Martinez-Bosch N, Guerrero PE, Vinaixa J, Dalotto-Moreno T, Iglesias M, Moreno M, Djurec M, Poirier F, Gabius HJ, Fernandez-Zapico ME, Hwang RF, Guerra C, Rabinovich GA, Navarro P.

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3769-E3778. doi: 10.1073/pnas.1722434115. Epub 2018 Apr 3.

7.

The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging.

Chini EN, Chini CCS, Espindola Netto JM, de Oliveira GC, van Schooten W.

Trends Pharmacol Sci. 2018 Apr;39(4):424-436. doi: 10.1016/j.tips.2018.02.001. Epub 2018 Feb 23. Review.

PMID:
29482842
8.

Pharmacological targeting of the mammalian clock reveals a novel analgesic for osteoarthritis-induced pain.

Das V, Kc R, Li X, Varma D, Qiu S, Kroin JS, Forsyth CB, Keshavarzian A, van Wijnen AJ, Park TJ, Stein GS, O-Sullivan I, Burris TP, Im HJ.

Gene. 2018 May 20;655:1-12. doi: 10.1016/j.gene.2018.02.048. Epub 2018 Feb 20. Erratum in: Gene. 2019 Jan 5;680:105.

PMID:
29474860
9.

Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.

DeLeon TT, Ahn DH, Bogenberger JM, Anastasiadis PZ, Arora M, Ramanathan RK, Aqel BA, Vasmatzis G, Truty MJ, Oklu R, Bekaii-Saab TS, Borad MJ.

Future Oncol. 2018 Mar;14(6):553-566. doi: 10.2217/fon-2017-0451. Epub 2018 Feb 20. Review.

PMID:
29460642
10.

Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.

Gupta S, Sahu D, Bomalaski JS, Frank I, Boorjian SA, Thapa P, Cheville JC, Hansel DE.

Endocr Pathol. 2018 Sep;29(3):236-241. doi: 10.1007/s12022-018-9516-9.

PMID:
29453600
11.

Inhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis.

Khosla S, Farr JN, Kirkland JL.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1282-1290. doi: 10.1210/jc.2017-02694. Review.

PMID:
29425296
12.

Targeting the stroma in pancreatic cancer.

Ahn DH, Ramanathan RK.

Chin Clin Oncol. 2017 Dec;6(6):65. doi: 10.21037/cco.2017.11.02.

13.

Epigenetic Therapy: Novel Translational Implications for Arrest of Environmental Dioxin-Induced Disease in Females.

Khan Z, Zheng Y, Jones TL, Delaney AA, Correa LF, Shenoy CC, Khazaie K, Daftary GS.

Endocrinology. 2018 Jan 1;159(1):477-489. doi: 10.1210/en.2017-00860.

PMID:
29165700
14.

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.

Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt DW, Goetz MP, Forero A, Bergqvist M, Karen J, Neumüller M, Suh EM, Guo Z, Vij K, Sanati S, Ellis M, Ma CX.

Breast Cancer Res. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7.

15.

Clinical Management of Cavernous Malformations.

Flemming KD.

Curr Cardiol Rep. 2017 Oct 18;19(12):122. doi: 10.1007/s11886-017-0931-1. Review.

PMID:
29046973
16.

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C.

Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.

17.

Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers.

Ahn DH, Grothey A.

Lancet Oncol. 2017 Nov;18(11):1427-1428. doi: 10.1016/S1470-2045(17)30714-3. Epub 2017 Sep 25. No abstract available.

PMID:
28958501
18.

Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.

Strickler JH, Wu C, Bekaii-Saab T.

Cancer Treat Rev. 2017 Nov;60:109-119. doi: 10.1016/j.ctrv.2017.08.006. Epub 2017 Aug 31. Review.

19.

Fatty acid synthase (FASN) as a therapeutic target in breast cancer.

Menendez JA, Lupu R.

Expert Opin Ther Targets. 2017 Nov;21(11):1001-1016. doi: 10.1080/14728222.2017.1381087. Epub 2017 Sep 21. Review.

PMID:
28922023
20.

Relamorelin for the treatment of gastrointestinal motility disorders.

Chedid V, Camilleri M.

Expert Opin Investig Drugs. 2017 Oct;26(10):1189-1197. doi: 10.1080/13543784.2017.1373088. Epub 2017 Aug 31. Review.

PMID:
28847163

Supplemental Content

Loading ...
Support Center